Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Caladrius extends retinal disease study
June 2015
SHARING OPTIONS:

NEW YORK—Caladrius Biosciences, formerly NeoStem, has extended its study for retinal disease thanks to a 2014 Early Translational grant from the California Institute of Regenerative Medicine for research leading to the development of a treatment for retinal diseases, including retinitis pigmentosa and macular degeneration. The grant, which totals $4 million, was made to the University of California, Irvine, and through a subaward, Caladrius Biosciences is entitled to $1 million of new funds adding to the original $500,000 that was awarded. The research’s focus is to generate 3D retinal tissue, to investigate whether adult induced pluripotent stem cells can restore sight in rodent models of retinal degeneration and to make preparations for clinical use of the tissue.
 
Dr. David J. Mazzo, Caladrius Biosciences’ CEO, noted that “This study exemplifies our commitment to utilizing non-dilutive funding sources for discovery programs exploring application of our technologies in other indications.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.